FAH

fumarylacetoacetate hydrolase

Basic information

Region (hg38): 15:80152490-80186946

Links

ENSG00000103876NCBI:2184OMIM:613871HGNC:3579Uniprot:P16930AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • tyrosinemia type I (Definitive), mode of inheritance: AR
  • tyrosinemia type I (Definitive), mode of inheritance: AR
  • tyrosinemia type I (Strong), mode of inheritance: AR
  • tyrosinemia type I (Definitive), mode of inheritance: AR
  • tyrosinemia type I (Definitive), mode of inheritance: AR
  • tyrosinemia type I (Supportive), mode of inheritance: AR
  • tyrosinemia type I (Definitive), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Tyrosinemia, type IARBiochemical; OncologicDietary (controlled intake of phenylalanine and tyrosine) and medical (eg, nitsinone) treatment can be beneficial, and may reduce risks related to manifestations (eg, hepatocellular carcinoma) that are part of the natural history in untreated individuals; Some individuals require liver transplantationBiochemical; Gastrointestinal; Musculoskeletal; Oncologic; Renal14085846; 14271358; 6016174; 2536631; 2153931; 2378357; 1383656; 1440864; 8028615; 7977370; 7603784; 8829657; 9101289; 9728331; 10603099; 11575602; 12203990; 15759101; 20301688; 22554029

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the FAH gene.

  • Tyrosinemia_type_I (728 variants)
  • not_provided (108 variants)
  • FAH-related_disorder (49 variants)
  • not_specified (47 variants)
  • Inborn_genetic_diseases (42 variants)
  • Tyrosinemia (3 variants)
  • Beta-D-mannosidosis (1 variants)
  • T-substance_anomaly (1 variants)
  • See_cases (1 variants)
  • Hypertyrosinemia (1 variants)
  • Tyrosinemia_type_II (1 variants)
  • Fumarylacetoacetase_pseudodeficiency (1 variants)
  • Hepatoblastoma (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the FAH gene is commonly pathogenic or not. These statistics are base on transcript: NM_000000137.4. Only rare variants are included in the table.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

EffectPLPVUSLBBSum
synonymous
1
clinvar
10
clinvar
187
clinvar
5
clinvar
203
missense
7
clinvar
38
clinvar
173
clinvar
12
clinvar
1
clinvar
231
nonsense
18
clinvar
17
clinvar
35
start loss
2
3
5
frameshift
21
clinvar
26
clinvar
2
clinvar
49
splice donor/acceptor (+/-2bp)
9
clinvar
42
clinvar
51
Total 57 127 185 199 6

Highest pathogenic variant AF is 0.00037998284

Loading clinvar variants...

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
FAHprotein_codingprotein_codingENST00000407106 1434457
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
4.03e-170.0056612561901291257480.000513
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense-0.03292442431.010.00001432765
Missense in Polyphen8897.4010.903481110
Synonymous-0.61310496.31.080.00000645806
Loss of Function-0.05812524.71.010.00000128268

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.001100.00110
Ashkenazi Jewish0.000.00
East Asian0.000.00
Finnish0.0007540.000739
European (Non-Finnish)0.0006600.000659
Middle Eastern0.000.00
South Asian0.0002290.000229
Other0.0003270.000326

dbNSFP

Source: dbNSFP

Pathway
Tyrosine metabolism - Homo sapiens (human);Tyrosinemia, transient, of the newborn;Dopamine beta-hydroxylase deficiency;Disulfiram Action Pathway;Phenylalanine and Tyrosine Metabolism;Tyrosine Metabolism;Alkaptonuria;Monoamine oxidase-a deficiency (MAO-A);Hawkinsinuria;Tyrosinemia Type I;Phenylketonuria;Tyrosinemia Type 3 (TYRO3);Tyrosinemia Type 2 (or Richner-Hanhart syndrome);Amino Acid metabolism;Citrate cycle;Histidine, lysine, phenylalanine, tyrosine, proline and tryptophan catabolism;Metabolism of amino acids and derivatives;Phenylalanine and tyrosine catabolism;Metabolism;tyrosine degradation;Tyrosine metabolism (Consensus)

Recessive Scores

pRec
0.243

Intolerance Scores

loftool
0.239
rvis_EVS
-0.91
rvis_percentile_EVS
10.03

Haploinsufficiency Scores

pHI
0.141
hipred
Y
hipred_score
0.564
ghis
0.508

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.981

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Fah
Phenotype
liver/biliary system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); neoplasm; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); renal/urinary system phenotype; cellular phenotype; immune system phenotype; homeostasis/metabolism phenotype; endocrine/exocrine gland phenotype; growth/size/body region phenotype;

Gene ontology

Biological process
arginine catabolic process;L-phenylalanine catabolic process;tyrosine catabolic process;homogentisate catabolic process
Cellular component
cytosol;extracellular exosome
Molecular function
fumarylacetoacetase activity;protein binding;metal ion binding